`U.S. Patent 8,536,122
`UNITED STATES PATENT AND TRADEMARK OFFICE
`______________________
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`______________________
`
`MYLAN PHARMACEUTICALS INC.,
`Petitioner
`
`v.
`
`NOVO NORDISK A/S,
`Patent Owner
`______________________
`Case IPR2023-00722
`Patent 8,536,122
`______________________
`
`PATENT OWNER’S MANDATORY NOTICES
`UNDER 37 C.F.R. § 42.8
`
`
`
`
`
`IPR2023-00722
`U.S. Patent 8,536,122
`Pursuant to 37 C.F.R. § 42.8, Patent Owner, Novo Nordisk A/S, hereby
`
`submits Mandatory Notice.
`
`I.
`
`REAL PARTIES-IN-INTEREST (37 C.F.R. § 42.8(b)(1))
`The real party-in-interest is Patent Owner Novo Nordisk A/S. Out of an
`
`abundance of caution, Patent Owner also identifies, as a potential real party-in-
`
`interest, exclusive licensee Novo Nordisk Inc. for purposes of providing notice.
`
`The listing of a potential real party-in-interest entity should not be deemed as an
`
`acknowledgement that, inter alia, any such entity actually controls this matter.
`
`II.
`
`RELATED MATTERS (37 C.F.R. § 42.8(b)(2))
` Novo Nordisk A/S identifies the following judicial and administrative
`
`matters that concern or concerned U.S. Patent No. 8,536,122.
`
`• Novo Nordisk Inc., et al. v. Viatris Inc., C.A. 23-13 (TSK) (N.D. W. Va.)
`
`• Novo Nordisk Inc., et al. v. Viatris Inc., C.A. 23-101 (CFC) (D. Del.)
`
`• Novo Nordisk Inc., et al. v. Mylan Pharmaceuticals Inc., C.A. 22-23 (IMK)
`
`(N.D. W. Va.) transferred to D. Del. as 22-1040 (CFC)
`
`• Novo Nordisk Inc. et al. v. Mylan Pharmaceuticals Inc., C.A. 22-1040
`
`(CFC) (D. Del.)
`
`• In re: Ozempic (Semaglutide) Patent Litigation, MDL No. 22-MD-3038
`
`(CFC) (D. Del.)
`
`1
`
`
`
`IPR2023-00722
`U.S. Patent 8,536,122
`• Novo Nordisk Inc. et al. v. Rio Biopharmaceuticals, Inc. et al., C.A. 22-294
`
`(CFC) (D. Del.)
`
`• Novo Nordisk Inc. et al. v. Aurobindo Pharma USA, Inc. et al., C.A. 22-295
`
`(CFC) (D. Del.)
`
`• Novo Nordisk Inc. et al. v. Sun Pharmaceuticals Industries Ltd. et al., C.A.
`
`22-296 (CFC) (D. Del.)
`
`• Novo Nordisk Inc. et al. v. Zydus Worldwide DMCC et al., C.A. 22-297
`
`(CFC) (D. Del.)
`
`• Novo Nordisk Inc. et al. v. Dr. Reddy’s Laboratories Ltd. et al., C.A. 22-298
`
`(CFC) (D. Del.)
`
`• Novo Nordisk Inc. et al. v. Alvogen, Inc., C.A. 22-299 (CFC) (D. Del.)
`
`The same petitioner has also challenged a related patent (No. 8,129,343) in
`
`IPR2023-00723.
`
`III. LEAD AND BACK-UP COUNSEL AND SERVICE
`INFORMATION UNDER §§42.8(b)(3)-(4):
`Lead:
`J. Steven Baughman (Reg. No. 47,414)
`GROOMBRIDGE, WU, BAUGHMAN & STONE LLP
`801 17th Street, NW, Suite 1050
`Washington, DC, 20006
`P: (202)-505-5832
`steve.baughman@groombridgewu.com
`
`
`Backup: Megan Raymond (Reg. No. 72,997)
`GROOMBRIDGE, WU, BAUGHMAN & STONE LLP
`
`2
`
`
`
`IPR2023-00722
`U.S. Patent 8,536,122
`
`801 17th Street, NW, Suite 1050
`Washington, DC, 20006
`P: (202)-505-5878
`megan.raymond@groombridgewu.com
`
`
`Novo Nordisk A/S consents to service through the counsel identified above.
`
`Electronic service of documents must be sent to each of the listed email
`
`
`
`addresses of the counsel and Novo-Semaglutide-IPR@groombridgewu.com. To
`
`the extent physical documents are served on Novo Nordisk A/S. please address any
`
`such correspondence to lead counsel and back-up counsel at the following mailing
`
`address: J. Steven Baughman, Megan Raymond, GROOMBRIDGE, WU,
`
`BAUGHMAN & STONE LLP, 801 17th Street, NW, Suite 1050, Washington,
`
`DC, 20006.
`
`
`
`Respectfully submitted,
`
`Dated: April 6, 2023
`
`
`
`By: /s/ Megan Raymond
`
`J. Steven Baughman (Reg. No. 47,414)
`GROOMBRIDGE, WU, BAUGHMAN & STONE LLP
`801 17th Street, NW, Suite 1050
`Washington, DC, 20006
`P: (202)-505-5832
`steve.baughman@groombridgewu.com
`
`Megan Raymond (Reg. No. 72,997)
`GROOMBRIDGE, WU, BAUGHMAN & STONE LLP
`801 17th Street, NW, Suite 1050
`Washington, DC, 20006
`
`3
`
`
`
`IPR2023-00722
`U.S. Patent 8,536,122
`
`P: (202)-505-5878
`megan.raymond@groombridgewu.com
`
`
`Attorneys for Patent Owner Novo Nordisk A/S
`
`
`
`4
`
`
`
`CERTIFICATE OF SERVICE
`
`IPR2023-00722
`U.S. Patent 8,536,122
`
`The undersigned hereby certifies that a copy of PATENT OWNER’S
`
`MANDATORY NOTICE UNDER 37 C.F.R. § 42.8 has been served in its entirety
`
`on April 6, 2023, by causing the aforementioned document to be electronically
`
`mailed to the following attorneys of record for the Petitioner listed below.
`
`Petitioner’s Counsel of Record:
`
`Lead Counsel:
`
`Brandon M. White
`Reg. No. 52,354
`White-ptab@perkinscoie.com
`Perkins Coie LLP
`700 13th Street, NW
`Washington, DC 20005
`Telephone: (202) 654-6200
`
`By Electronic Mail
`Backup Counsel: Emily J. Greb
`Reg. No. 68,244
`Greb-ptab@perkinscoie.com
`Perkins Coie LLP
`33 East Main Street
`Madison, WI 53703
`Telephone: (608) 663-7460
`
`Courtney Prochnow, PhD
`Reg. No. 67,639
`Prochnow-ptab@perkinscoie.com
`Perkins Coie LLP
`633 W. 5th St., Ste 5850
`Los Angeles, CA 90071
`Telephone: (310) 788-9900
`
`Christopher D. Jones
`Reg. No. 76,472
`Jones-ptab@perkinscoie.com
`
`5
`
`
`
`IPR2023-00722
`U.S. Patent 8,536,122
`
`Perkins Coie LLP
`700 13th Street, NW
`Washington, DC 20005
`Telephone: (202) 654-6200
`
`Jonathan I. Tietz, PhD
`Reg. No. 76,753
`Tietz-ptab@perkinscoie.com
`Perkins Coie LLP
`700 13th Street, NW
`Washington, DC 20005
`Telephone: (202) 654-6200
`
`Matthew A. Lembo
`Reg. No. 75,633
`Lembo-ptab@perkinscoie.com
`Perkins Coie LLP
`1155 Avenue of the Americas
`Floor 22
`New York, NY 10036
`Telephone: (212) 262-6900
`
`Semaglutide-Ozempic@perkinscoie.com
`By Electronic Mail
`
`Dated: April 6, 2023
`
`
`
`
`
` Respectfully submitted,
`By: /Sayem Osman
`Sayem Osman
`
`6
`
`